Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
1970 1
1982 1
1987 2
1990 3
1991 1
1992 3
1993 2
1994 5
1995 6
1996 6
1997 8
1998 8
1999 7
2000 12
2001 17
2002 22
2003 12
2004 13
2005 8
2006 12
2007 15
2008 14
2009 6
2010 10
2011 16
2012 11
2013 14
2014 14
2015 15
2016 23
2017 7
2018 14
2019 14
2020 14
2021 15
2022 12
2023 10
2024 5

Text availability

Article attribute

Article type

Publication date

Search Results

337 results

Results by year

Filters applied: . Clear all
Page 1
Response.
Lambertini M, Ameye L, Paesmans M, Peccatori FA, Azim HA Jr. Lambertini M, et al. Among authors: paesmans m. J Natl Cancer Inst. 2018 Aug 1;110(8):919-920. doi: 10.1093/jnci/djx292. J Natl Cancer Inst. 2018. PMID: 29329404 No abstract available.
Empiric vs Preemptive Antifungal Strategy in High-Risk Neutropenic Patients on Fluconazole Prophylaxis: A Randomized Trial of the European Organization for Research and Treatment of Cancer.
Maertens J, Lodewyck T, Donnelly JP, Chantepie S, Robin C, Blijlevens N, Turlure P, Selleslag D, Baron F, Aoun M, Heinz WJ, Bertz H, Ráčil Z, Vandercam B, Drgona L, Coiteux V, Llorente CC, Schaefer-Prokop C, Paesmans M, Ameye L, Meert L, Cheung KJ, Hepler DA, Loeffler J, Barnes R, Marchetti O, Verweij P, Lamoth F, Bochud PY, Schwarzinger M, Cordonnier C; Infectious Diseases Group and the Acute Leukemia Group of the European Organization for Research and Treatment of Cancer. Maertens J, et al. Among authors: paesmans m. Clin Infect Dis. 2023 Feb 18;76(4):674-682. doi: 10.1093/cid/ciac623. Clin Infect Dis. 2023. PMID: 35906831 Free PMC article. Clinical Trial.
Paclitaxel plus carboplatin and durvalumab with or without oleclumab for women with previously untreated locally advanced or metastatic triple-negative breast cancer: the randomized SYNERGY phase I/II trial.
Buisseret L, Loirat D, Aftimos P, Maurer C, Punie K, Debien V, Kristanto P, Eiger D, Goncalves A, Ghiringhelli F, Taylor D, Clatot F, Van den Mooter T, Ferrero JM, Bonnefoi H, Canon JL, Duhoux FP, Mansi L, Poncin R, Barthélémy P, Isambert N, Denis Z, Catteau X, Salgado R, Agostinetto E, de Azambuja E, Rothé F, Craciun L, Venet D, Romano E, Stagg J, Paesmans M, Larsimont D, Sotiriou C, Ignatiadis M, Piccart-Gebhart M. Buisseret L, et al. Among authors: paesmans m. Nat Commun. 2023 Nov 2;14(1):7018. doi: 10.1038/s41467-023-42744-y. Nat Commun. 2023. PMID: 37919269 Free PMC article. Clinical Trial.
BrainStorm: a multicenter international study to tackle CNS metastases in solid tumors.
Martins-Branco D, Nader-Marta G, Gombos A, Barthelemy P, Goncalves A, Borcoman E, Clatot F, Holbrechts S, De Maio D'Esposito E, Cheymol C, Vanhaudenarde V, Duhoux FP, Duhem C, Decoster L, Denys H, Lefranc F, Canon JL, Clement PM, Gligorov J, Paesmans M, Kindt N, Awada A, Kotecki N. Martins-Branco D, et al. Among authors: paesmans m. Nat Med. 2023 Dec;29(12):2981-2982. doi: 10.1038/s41591-023-02595-y. Nat Med. 2023. PMID: 37857713 No abstract available.
Ki-67 index after neoadjuvant endocrine therapy as a prognostic biomarker in patients with ER-positive/HER2-negative early breast cancer: a systematic review and meta-analysis.
Martins-Branco D, Nader-Marta G, Molinelli C, Ameye L, Paesmans M, Ignatiadis M, Aftimos P, Salgado R, de Azambuja E. Martins-Branco D, et al. Among authors: paesmans m. Eur J Cancer. 2023 Nov;194:113358. doi: 10.1016/j.ejca.2023.113358. Epub 2023 Sep 22. Eur J Cancer. 2023. PMID: 37857118
First-in-human study of SBRT and adenosine pathway blockade to potentiate the benefit of immunochemotherapy in early-stage luminal B breast cancer: results of the safety run-in phase of the Neo-CheckRay trial.
De Caluwe A, Romano E, Poortmans P, Gombos A, Agostinetto E, Marta GN, Denis Z, Drisis S, Vandekerkhove C, Desmet A, Philippson C, Craciun L, Veys I, Larsimont D, Paesmans M, Van Gestel D, Salgado R, Sotiriou C, Piccart-Gebhart M, Ignatiadis M, Buisseret L. De Caluwe A, et al. Among authors: paesmans m. J Immunother Cancer. 2023 Dec 6;11(12):e007279. doi: 10.1136/jitc-2023-007279. J Immunother Cancer. 2023. PMID: 38056900 Free PMC article. Clinical Trial.
Real-world clinical outcomes of patients with stage I HER2-positive breast cancer treated with adjuvant paclitaxel and trastuzumab.
Debien V, Marta GN, Agostinetto E, Sirico M, Jacobs F, Molinelli C, Moreau M, Paesmans M, De Giorgi U, Santoro A, Taylor D, Duhoux FP, Botticelli A, Barchiesi G, Speranza I, Lambertini M, Wildiers H, Azambuja E, Piccart M. Debien V, et al. Among authors: paesmans m. Crit Rev Oncol Hematol. 2023 Oct;190:104089. doi: 10.1016/j.critrevonc.2023.104089. Epub 2023 Aug 9. Crit Rev Oncol Hematol. 2023. PMID: 37562696 Review.
Author Correction: Paclitaxel plus carboplatin and durvalumab with or without oleclumab for women with previously untreated locally advanced or metastatic triple-negative breast cancer: the randomized SYNERGY phase I/II trial.
Buisseret L, Loirat D, Aftimos P, Maurer C, Punie K, Debien V, Kristanto P, Eiger D, Goncalves A, Ghiringhelli F, Taylor D, Clatot F, Van den Mooter T, Ferrero JM, Bonnefoi H, Canon JL, Duhoux FP, Mansi L, Poncin R, Barthélémy P, Isambert N, Denis Z, Catteau X, Salgado R, Agostinetto E, de Azambuja E, Rothé F, Craciun L, Venet D, Romano E, Stagg J, Paesmans M, Larsimont D, Sotiriou C, Ignatiadis M, Piccart-Gebhart M. Buisseret L, et al. Among authors: paesmans m. Nat Commun. 2023 Dec 12;14(1):8223. doi: 10.1038/s41467-023-44071-8. Nat Commun. 2023. PMID: 38086864 Free PMC article. No abstract available.
Molecular imaging predicts lack of T-DM1 response in advanced HER2-positive breast cancer (final results of ZEPHIR trial).
Mileva M, de Vries EGE, Guiot T, Wimana Z, Deleu AL, Schröder CP, Lefebvre Y, Paesmans M, Stroobants S, Huizing M, Aftimos P, Tol J, Van der Graaf WTA, Oyen WJG, Vugts DJ, Menke-van der Houven van Oordt CW, Brouwers AH, Piccart-Gebhart M, Flamen P, Gebhart G. Mileva M, et al. Among authors: paesmans m. NPJ Breast Cancer. 2024 Jan 6;10(1):4. doi: 10.1038/s41523-023-00610-6. NPJ Breast Cancer. 2024. PMID: 38184611 Free PMC article.
337 results